BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 2272605)

  • 1. Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia.
    Parhofer KG; Richter WO; Schwandt P
    Horm Metab Res; 1990 Nov; 22(11):589-94. PubMed ID: 2272605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E polymorphism in type 2 diabetic patients of Talca, Chile.
    Leiva E; Mujica V; Orrego R; Prieto M; Arredondo M
    Diabetes Res Clin Pract; 2005 Jun; 68(3):244-9. PubMed ID: 15936467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of apolipoprotein E genotype on lipid levels and response to diet in familial hypercholesterolemia.
    Carmena-Ramón R; Real JT; Ascaso JF; Ordovás JM; Carmena R
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):7-13. PubMed ID: 10812582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E polymorphism in Turkish subjects with Type 2 diabetes mellitus: allele frequency and relation to serum lipid concentrations.
    Duman BS; Oztürk M; Yilmazer S; Hatemi H
    Diabetes Nutr Metab; 2004 Oct; 17(5):267-74. PubMed ID: 16295048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein e4 allele and the risk of CAD death in type 2 diabetes mellitus with ischaemia electrocardiographic change.
    Guang-da X; Xiang-Jiu Y; Lin-Shuang Z; Zhi-Song C; Yu-Sheng H
    Diabetes Res Clin Pract; 2005 Jun; 68(3):223-9. PubMed ID: 15936464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.
    Utermann G; Vogelberg KH; Steinmetz A; Schoenborn W; Pruin N; Jaeschke M; Hees M; Canzler H
    Clin Genet; 1979 Jan; 15(1):37-62. PubMed ID: 215360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frequency of apolipoprotein epsilon 4 allele in type II diabetes with hypercholesterolemia.
    Eto M; Watanabe K; Iwashima Y; Morikawa A; Chonan N; Oshima E; Sekiguchi M; Ishii K
    Diabetes; 1987 Nov; 36(11):1301-6. PubMed ID: 3666320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus.
    Eto M; Watanabe K; Sato T; Makino I
    J Clin Endocrinol Metab; 1989 Dec; 69(6):1207-12. PubMed ID: 2584356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese.
    Kitahara M; Shinomiya M; Shirai K; Saito Y; Yoshida S
    Atherosclerosis; 1990 Jun; 82(3):197-204. PubMed ID: 2375785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients.
    Kwon MK; Rhee SY; Chon S; Oh S; Woo JT; Kim SW; Kim JW; Kim YS; Jeong KH; Lee SH; Lee TW; Ihm CG
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S228-32. PubMed ID: 17624465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels.
    Saidi S; Slamia LB; Ammou SB; Mahjoub T; Almawi WY
    J Stroke Cerebrovasc Dis; 2007; 16(4):160-6. PubMed ID: 17689412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Apolipoprotein E and its alleles in healthy subjects and in atherosclerosis].
    Couderc R; Bailleul S
    Ann Biol Clin (Paris); 1998; 56(6):651-9. PubMed ID: 9853024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
    Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on apoE gene polymorphism and subclasses of serum high density lipoprotein in type IV hyperlipidemia].
    Tian Y; Long SY; Xu YH; Fu MD; Zhang XM; Liu BW
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Feb; 22(1):96-8. PubMed ID: 15696494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.